Navigation Links
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Date:1/3/2008

Novel non-estrogen oral therapy in development for menopausal symptoms

ANN ARBOR, Mich., Jan. 3 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced positive results from a pivotal Phase 3 study of Ophena(TM) (ospemifene) to treat postmenopausal women with vulvovaginal atrophy, a common condition associated with menopause. Top line data show that the multi-center, double-blind, placebo-controlled study successfully met all of its co-primary endpoints. The study was conducted in 80 U.S. centers and involved more than 800 women. Full results of the study are being submitted to an upcoming scientific meeting for release later in 2008.

Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a treatment for women with postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy. PVS is a common condition in postmenopausal women characterized by symptoms such as vaginal dryness, irritation and pain associated with sexual intercourse. The only currently FDA approved products for this condition all contain the hormone estrogen. However, many women and their physicians avoid using estrogen-containing products due to concerns about the risks of such therapy identified in the Women's Health Initiative (WHI) and other studies.

"These results are very exciting and we believe demonstrate that Ophena(TM) has the potential to bring clear clinical benefit to women affected by PVS, many of whom have had only estrogen therapy as a treatment option for their condition to date," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe Ophena(TM) could provide the first non- estrogen prescription treatment alternative for this condition. QuatRx is well positioned to continue with our plans to advance this exciting product to commercialization, pending regulatory review and approval."

This pivotal Phase 3 study was designed to evaluate the efficacy of Ophena(TM) versus p
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 VWR (NASDAQ: VWR ... solutions, announces the redesign of its global website, www.vwr.com ... When visiting the new site, guests will enjoy enhanced content ... vivid images.  Each country site now includes: ... product menu; and , the ability to search by ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... , NEW YORK , Jan. ... development of transformative treatments for Parkinson,s disease, The Michael J. ... $2.1 million in awards to six biotech and pharmaceutical ... The funding will drive pre-clinical projects pushing forward investigations of ...
... , ATLANTA , ... the market leader in automated revenue integrity solutions that improve ... its first customer. , Supplies ChargeLink™ is ... reimbursement for chargeable supplies. It does this by establishing and ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies 2Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies 3Craneware's New Product Reduces Supply Chain Revenue Leakage 2Craneware's New Product Reduces Supply Chain Revenue Leakage 3Craneware's New Product Reduces Supply Chain Revenue Leakage 4
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to ... by diabetes after many years of suffering and using medications with strong side effects. ... to ask for extra time off or wait longer hours in the waiting rooms. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/3/2015)... ... , ... Recent reports by the American Medical Association show that over 80% ... Often time, low back and sciatic pain can happen as a result of vertebral ... powerful pain medication or spinal surgery. Dynamic Health Care in Louisville, KY , ...
(Date:8/2/2015)... ... 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can prove ... afford to start a business.” Neither needs be a major obstacle. , The U.S. ... start a business and be successful. The risks of starting a business can be high ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
... eat whatever she wants and still fit into her prom dress, ... chocolate cake. Before you sign up for Weight Watchers and that ... research from Tel Aviv University and save yourself a few hundred ... rigorous exercise and abstaining from sweets than it does with the ...
... 1, 2008) Many patients who come to ... (PCI) are already taking 75mg of clopidogrel daily ... additional 600-mg reloading dose of clopidogrel significantly improves ... only in patients with acute coronary syndromes (ACS), ...
... 1, 2008) A study in which interventional cardiologists ... using a needle-tipped catheter has reported mixed results in ... of Implanted (Autologous) Skeletal Myoblasts (MyoCell) using an Injection ... but no evidence that the heart was able to ...
... Stimulus ... Means to Address Social Issues, DETROIT, April 1, 2008 ... total of $50,000 in grants to,the Detroit Renaissance Foundation ($25,000) ... programs,demonstrating a broader scope for the charitable organization. In addition,Ilitch ...
... Va., April 1, 2008 The following,is being ... Diabetes Association,s 68th Annual Scientific Sessions., WHEN: ... Moscone Center, San Francisco, CA, WHY: More ... care,professionals from around the world will share cutting-edge ...
... plan for future of loved ones with special ... ... Massachusetts Mutual,Life Insurance Company (MassMutual) today made available on its Web site ... to begin,developing or supplementing life care plans for family members with a,disability ...
Cached Medicine News:Health News:The lean gene 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2Health News:SEISMIC study issues glum report on cell therapy 2Health News:Ilitch Charities Invests $50,000 in Innovative Community Programs 2Health News:Ilitch Charities Invests $50,000 in Innovative Community Programs 3Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 3
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Medicine Products: